Bibliography
- Revillion F, Bonneterre J, Peyrat JP. ErbB-2 oncogene in human breast cancer and its clinical significance. Eur J Cancer 1998;34:791-808
- Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of HER2/neu oncogene. Science 1987;235:177-82
- Wright C, Angus B, Nicholson S, et al. Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res 1989;49:2087-90
- Tandon AK, Clark GM, Chamness GC, et al. HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol 1989;7:1120-8
- Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639-48
- Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92
- Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-72
- Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-84
- Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354:809-20
- Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355:2733-43
- Gomez HL, Doval DC, Chavez MA, et al. Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol 2008;26:2999-3005
- Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-26
- Johnston S, Trudeau M, Kaufman B, et al. Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy. J Clin Oncol 2008;26:1066-72
- Burstein HJ, Storniolo AM, Franco S, et al. A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer. Ann Oncol 2008;19:1068-74
- Perez P, Hoffman RW, Shaw S, et al. Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody. Nature 1985;316:354-6
- Fanger MW, Segal DM, Wunderlich JR. Going both ways: bispecific antibodies and targeted cellular cytotoxicity. FASEB J 1990;4:2846-9
- Weiner LM, Clark JI, Ring DB, Alpaugh RK. Clinical development of 2B1, a bispecific murine monoclonal antibody targeting c-erbB-2 and Fc gamma RIII. J Hematother 1995;4:453-6
- Valerius T, Stockmeyer B, van Spriel AB, et al. FcalphaRI (CD89) as a novel trigger molecule for bispecific antibody therapy. Blood 1997;90:4485-92
- Lum LG, Rathore R, Cummings F, et al. Phase I/II Study of treatment of stage IV breast cancer with OKT3 x trastuzumab-armed activated T-cells. Clin Breast Cancer 2003;4:212-7
- Herrmann T, Grosse-Hovest L, Otz T, et al. Construction of optimized bispecific antibodies for selective activation of the death receptor CD95. Cancer Res 2008;68:1221-7
- Repp R, van Ojik HH, Valerius T, et al. Phase I clinical trial of the bispecific antibody MDX-H210 (anti-FcgammaRI × anti-HER-2/neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer. Br J Cancer 2003;89:2234-43
- Lindhofer H, Mocikat R, Steipe B, Thierfelder S. Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies. J Immunol 1995;155:219-55
- Zeidler R, Mysliwietz J, Csanady M, et al. The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumor cells. Br J Cancer 2000;83:261
- Zeidler R, Reisbach G, Wollenberg B, et al. Simultaneous activation of T-cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing. J Immunol 1999;163:1246-52
- Riesenberg R, Buchner A, Pohla H, Lindhofer H. Lysis of prostate carcinoma cells by trifunctional bispecific antibodies (alpha EpCAM × alpha CD3). J Histochem Cytochem 2001;49:911-7
- Riechelmann H, Wiesneth M, Schauwecker P, et al. Adoptive therapy of head and neck squamous cell carcinoma with antibody coated immune cells: a pilot clinical trial. Cancer Immunol Immunother 2007;56:1397-406
- Jäger M, Ruf P, Schoberth A, et al. Effect on low HER2 (1+) expressing tumor cells of the trifunctional antibody ertumaxomab [abstract 3071]. J Clin Oncol 2008;26(Suppl):149s
- Leidig T, Wawrsinek F, Lindemann C, Mueller-Klieser W. The trifunctional antibodies catumaxomab and ertumaxomab demonstrate efficacy in co-cultures of human multicellular tumor spheroids (MCTS) and peripheral blood mononuclear cells (PBMC) [abstract no. 399]. In: Proceedings of the 99th Annual Meeting of the American Association for Cancer Research; 12 – 16 April 2008; San Diego, CA
- Lindhofer H, Menzel H, Zengerle U, et al. Bispecific antibodies effectively purge cancer cells from peripheral blood stem cell collections without affecting colony forming units. Exp Hematol 1997;25:879
- Kiewe P, Hasmüller S, Kahlert S, et al. Phase I trial of the trifunctional anti-HER2 × anti-CD3 antibody ertumaxomab in metastatic breast cancer. Clin Cancer Res 2006;12:3085-91
- Heiss MM, Strohlein MA, Jäger M, et al. Immunotherapy of malignant ascites with trifunctional antibodies. Int J Cancer 2005;117:435-43
- Parsons SL, Murawa X, Koralewski P, et al. Intraperitoneal treatment of malignant ascites due to epithelial tumors with catumaxomab: a phase II/III study [abstract 3000]. J Clin Oncol 2008;26(Suppl):132s
- Ruf P, Lindhofer H. Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody. Blood 2001;98:2526-34
- Borghaei H, Alpaugh RK, Bernardo P, et al. Induction of adaptive Anti-HER2/neu immune responses in a phase 1B/2 trial of 2B1 bispecific murine monoclonal antibody in metastatic breast cancer (E3194): a trial coordinated by the Eastern Cooperative Oncology Group. J Immunother 2007;30:455-67
- Weiner LM, Clark JI, Davey M, et al. Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and Fc gamma RIII. Cancer Res 1995;55:4586-93
- Kroesen BJ, Janssen RA, Buter J, et al. Bispecific monoclonal antibodies for intravenous treatment of carcinoma patients: immunobiologic aspects. J Hematother 1995;4:409-14
- Rusnak DW, Affleck K, Cockerill SG, et al. The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer. Cancer Res 2001;61:7196-203